Newsletter summary

[Kang Fang Bio's afternoon decline narrowed down the company denied that clinical data were lower than expected] according to the Securities Times, Kang Fang Bio (09926 JK) plunged sharply in intraday trading on the 24th, falling about 45% at one point, and the decline gradually narrowed in the afternoon. As of press time, the stock fell about 20%, with a market capitalization of about HK $33 billion. TodayBestnumbersforpowerball...

Text of news flash

[Kang Fang Bio's afternoon decline narrowed down the company denied that clinical data were lower than expected] according to the Securities Times, Kang Fang Bio (09926 JK) plunged sharply in intraday trading on the 24th, falling about 45% at one point, and the decline gradually narrowed in the afternoon. As of press time, the stock fell about 20%, with a market capitalization of about HK $33 billion. Today, there is market news that Kang Fang biological AK112 in the treatment of EGFR-TKi non-small cell lung cancer Chinese phase Ⅲ clinical data are not as expected. Subsequently, the company responded that the HR corresponding to the AK112 progression-free survival disclosed by the American Society of Clinical Oncology (ASCO) in 2024 was 0.46, which is the core data for evaluating clinical research results, and there is no lower-than-expected statement. With excellent results, the data of AK112-301have been accepted as an oral report by the 2024ASCO Conference and will be released to the world on June 1st as planned by the organizers. At the same time, the company announced that the State Drug Administration (NMPA) has approved the application for the listing of the world's first bispecific antibody drug Yida Fang (Yiwoxi injection, PD-1/VEGF) independently developed by the company. The indication is combined chemotherapy for locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) with EGFR mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine mycosis inhibitor (TKI). Kang Fang Bio said that Ida Fang? (Yiwoxi injection) is the company's independent research and development, the world's first PD-1/VEGF bispecific tumor immunotherapy drug. Yidafong? It was approved by the State Drug Administration of China in May 2024 for the treatment of locally advanced or metastatic nsq-NSCLC after EGFR-TKI treatment. At present, Ivosi has a comprehensive population distribution of lung cancer patients, and a number of head-to-head studies are under way, such as the phase III study of single agent versus pabrizumab alone in the treatment of PD-L1-positive NSCLC, phase III study of combination chemotherapy versus tirizumab combined with first-line chemotherapy in sqNSCLC, and the global multicenter phase III study of combination chemotherapy with tirizumab and first-line chemotherapy in sqNSCLC. Clinical trials covering 16 indications such as digestive tract tumors, hepatocellular carcinoma and colorectal cancer are under way. After making a reasonable inquiry about the company, the board of directors confirms that it is not aware of any such company which may cause unusual fluctuations in the price or trading volume of the company's shares or must be disclosed to avoid a false market in the company's securities.BestnumbersforpowerballHis information or any inside information required to be disclosed under part XIVA of the Securities and Futures Ordinance (Cap. 571). Kangfang Bio also suggested that the company could not guarantee that the company would eventually successfully develop and sell Ida Fang (YVOS, PD-1/VEGF). Shareholders and potential investors are advised to exercise caution when buying and selling shares in the company. Proofread: Tao Qian